rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SYRE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Spyre Therapeutics: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceSYRE
      Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
      Oct 24Yahoo FinanceSYRE
      Spyre presents clinical data on IBD antibody therapies
      Oct 18Investing.comSYRE
      Jefferies says this stock remains a top pick among biotech midcaps

      Investing.com-- Jefferies said Spyre Therapeutics remained its top pick in the small- to mid-cap biotech sector heading into 2027, lauding its pipeline of combination therapies for inflammatory bowel disease.

      Oct 16Yahoo FinanceSYRE
      Spyre Therapeutics (SYRE) Receives a Buy from UBS

      Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

      Oct 12The Globe and MailSYRE
      UBS Initiates Spyre Therapeutics at Buy With $120 Price Target
      Oct 12Yahoo FinanceSYRE
      UBS initiates Spyre stock with buy rating on IBD therapy potential
      Oct 12Investing.comSYRE
      Why is Spyre Therapeutics stock rallying today?
      Oct 9Investing.comSYRE
      Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
      Oct 8Yahoo FinanceSYRE
      Spyre Therapeutics Announces Major Equity Financing Agreement

      Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailSYRE
      Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026

      Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. Read more on SYRE.

      Oct 7Seeking AlphaSYRE
      Update: Spyre Shares Fall After Pricing $350 Million Stock Offering
      Oct 6Yahoo FinanceSYRE
      Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
      Oct 6Yahoo FinanceSYRE
      Why is Spyre Therapeutics stock sliding today?
      Oct 6Investing.comSYRE
      Spyre Therapeutics stock falls on public offering launch
      Oct 6Investing.comSYRE
      Spyre Therapeutics prices $350M stock offering at $85/share
      Oct 6Investing.comSYRE
      Spyre Therapeutics stock falls on public offering launch

      Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company’s announcement of an underwritten public offering of its common stock.

      Oct 5Yahoo FinanceSYRE
      Spyre Therapeutics launches public stock offering
      Oct 5Investing.comSYRE
      Spyre Therapeutics Commences Public Offering of Common Stock
      Oct 5Yahoo FinanceSYRE
      Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
      Oct 5Yahoo FinanceSYRE
      Spyre Therapeutics Insider Sold Shares Worth $2,261,831, According to a Recent SEC Filing
      Oct 5Yahoo FinanceSYRE
      Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

      Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

      Oct 4The Globe and MailSYRE
      Spyre Therapeutics’ chief legal officer sells $2.63m in shares
      Oct 3Investing.comSYRE
      Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock
      Oct 3Investing.comSYRE
      Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock
      Oct 3Investing.comSYRE
      Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ)

      Spyre Therapeutics (SYRE) stock jumps as J.P. Morgan starts coverage with an Overweight rating and a $110 target for 2027 year-end. Read more here.

      Oct 1Seeking AlphaSYRE
      Why is Spyre Therapeutics stock climbing today?
      Oct 1Investing.comSYRE
      JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target
      Oct 1Yahoo FinanceSYRE
      JPMorgan initiates Spyre stock with Overweight on IBD pipeline
      Oct 1Investing.comSYRE
      Why is Spyre Therapeutics stock rallying today?
      Sep 30Investing.comSYRE
      Spyre Therapeutics at Stifel forum: betting on autoimmune combinations
      Sep 23Investing.comSYRESF
      What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?

      Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...

      Sep 22Yahoo FinanceSYRE
      Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

      On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]

      Sep 17Yahoo FinanceSYRE
      Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

      Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]

      Sep 10Yahoo FinanceSYRE
      Spyre Therapeutics at Wells Fargo conference: betting on combination biologics
      Sep 10Investing.comSYREWFC
      Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

      Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailSYRE
      Spyre Therapeutics at Citi summit: bets on autoimmune combinations
      Sep 9Investing.comSYRE
      Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

      SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.

      Sep 9Yahoo FinanceSYRE
      Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data
      Sep 9Investing.comSYRE
      Baird reiterates Spyre stock Outperform rating on positive trial data
      Sep 9Investing.comSYRE
      Spyre reports positive ulcerative colitis trial data for SPY003
      Sep 8Investing.comSYRE
      Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

      SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYL

      Sep 8Yahoo FinanceSYRE
      Spyre Therapeutics Announces Grants of Inducement Awards

      WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase

      Sep 4Yahoo FinanceSYRE
      Spyre Therapeutics Insider Sold Shares Worth $2,283,821, According to a Recent SEC Filing

      Scott L Burrows, Chief Financial Officer, on September 01, 2026, sold 25,732 shares in Spyre Therape

      Sep 4Yahoo FinanceSYRE
      Spyre Therapeutics Insider Sold Shares Worth $2,480,529, According to a Recent SEC Filing

      Heidy King-Jones, Chief Legal Officer and Corporate Secretary, on September 01, 2026, sold 28,399 sh

      Sep 4Yahoo FinanceSYRE
      Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing

      Cameron Turtle, Director, Chief Executive Officer, on September 01, 2026, sold 15,000 shares in Spyr

      Sep 4Yahoo FinanceSYRE
      Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares
      Sep 4Investing.comSYRE
      Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares
      Sep 4Investing.comSYRE
      Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares
      Sep 4Investing.comSYRE
      Spyre Therapeutics to Participate in Upcoming September Investor Conferences

      WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event: Citi 2026 BioPharma Back to School Conference – New YorkDate:

      Sep 3Yahoo FinanceSYRE

      This is the newest page. Registered accounts read further back.